Previous 10 | Next 10 |
On-going Phase 2b clinical trial (ASPEN-COVID-19) evaluating rNAPc2 as a potential treatment for COVID-19 DSMC interim analysis of safety and efficacy data from ASPEN-COVID-19 completed with recommendation to continue trial to completion with no modifications T...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! It’s the last day of the trading week and we’re starting it with a dive into the biggest pre-market stock movers for Friday! Source: f11photo/Shutterstock.com We’ve got p...
ARCA biopharma (NASDAQ:ABIO) announces that the Data and Safety Monitoring Committee (DSMC) has recommended completing the company's Phase 2b study of rNAPc2 in treating COVID-19 with no modifications to the trial design. Shares jump more than 30% post market. The rec...
Enrollment completion anticipated by year end 2021 Topline data anticipated in first quarter of 2022 WESTMINSTER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approac...
Direxion is planning to launch the Direxion mRNA ETF to offer investors exposure to messenger RNA technology, the cutting-edge research area that served as the basis for most COVID-19 vaccines. Per a prospectus filed with the U.S. Securities and Exchange Commission, the new ETF will...
First international patient enrolled in Brazil Trial approximately 75% enrolled rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients Topline trial data anticipated in the fourth quarter of 2021 WESTMINS...
The following slide deck was published by ARCA biopharma, Inc. in conjunction with this event. For further details see: ARCA biopharma (ABIO) Investor Presentation - Slideshow
WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Jeff Dekker , Chief Financial ...
ARCA biopharma Inc. (NASDAQ: ABIO) is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COV...
WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that it has submitted a Patent Cooperat...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sale...
ARCA biopharma and Oruka Therapeutics announce Merger Agreement ARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company app...